shortagewatch

Home / Companies / Nissin Pharmaceutical

Company family · HQ JP

Nissin Pharmaceutical: medicine shortages

As of 2 Nov 2026, 18 Nissin Pharmaceutical products have a reported shortage across 1 countries, covering 8 medicines.

Products short18rank #125 of 464
Medicines8active ingredients
Countries1/16
New in 90 days7+1 vs market pace
Typical duration6 monthsmedian so far
Manufacturing44%demand-driven 33%

Where

Japan18

Which therapeutic classes

Sensory organs6Blood3Musculoskeletal system1Digestive tract and metabolism1Nervous system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Nissin PharmaceutiNissin Pharmaceuti: Manufacturing problem 8 (44%)44%Nissin Pharmaceuti: Increased demand 6 (33%)33%Nissin Pharmaceuti: Active ingredient shortage 2 (11%)11%Nissin Pharmaceuti: Other 2 (11%)11%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

025710Dec: 0Jan ’25: 0Feb: 1FebMar: 0Apr: 0May: 0MayJun: 0Jul: 2Aug: 0AugSep: 0Oct: 1Nov: 0NovDec: 2Jan ’26: 0Feb: 0FebMar: 2Apr: 0May: 3MayJun: 0Jul: 0Aug: 0AugSep: 1Oct: 6Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Nissin Pharmaceutical18

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Nissin Pharmaceutical: 18 / 8Nissin Pharmaceutical

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Lidocaine311 May 2026Increased demand1/16
Hyaluronic Acid29 Mar 2026Other1/16
Tranexamic Acid217 Dec 2025Manufacturing problem10/16
Ascorbic Acid19 Oct 2026Manufacturing problem1/16
Eperisone112 Feb 2025Increased demand1/16
Famotidine19 Oct 2026Manufacturing problem4/16
Memantine114 Sep 2026Increased demand8/16
Sodium Bicarbonate19 Oct 2026Manufacturing problem3/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.